Related Experiment Videos
Intra-arterial chemotherapy for brain tumors
S J Hassenbusch1, J H Anderson, D M Whiting
1Department of Neurosurgery, Cleveland Clinic Foundation, Ohio 44195-5226.
Cleveland Clinic Journal of Medicine
|September 1, 1990
Summary
Optimizing brain tumor therapy requires comparing theoretical models with actual drug delivery. Using perfluorocarbons as a diluent for carmustine (BCNU) significantly improved drug delivery ratios compared to ethanol, leading to successful human trials.
Area of Science:
- Pharmacology
- Neuro-oncology
- Biomedical Engineering
Background:
- Direct comparison of theoretical pharmacokinetic modeling with actual drug delivery is crucial for advancing brain tumor therapies.
- Carmustine (BCNU) is a chemotherapeutic agent used in brain tumor treatment, but its delivery efficiency can be a challenge.
- Previous theoretical models predicted specific drug concentration ratios, but experimental validation was needed.
Purpose of the Study:
- To compare the efficacy of different diluents (ethanol vs. hyperoxygenated perfluorocarbons) for carmustine (BCNU) delivery in brain tumor models.
- To evaluate the accuracy of theoretical pharmacokinetic modeling in predicting BCNU distribution.
- To translate laboratory findings into a clinical protocol for human brain tumor patients.
Main Methods:
- Normal and brain tumor-bearing rabbits received infusions of carmustine (BCNU) using either ethanol or hyperoxygenated perfluorocarbons as the diluent.
- BCNU concentrations were measured in the infused (right) and noninfused (left) cerebral hemispheres.
- Pharmacokinetic data from animal studies were used to inform a two-phase human clinical trial protocol.
Main Results:
- When ethanol was used as a diluent, the measured BCNU concentration ratios between hemispheres were significantly lower than predicted by theoretical models in both normal and tumor-bearing rabbits.
- Using hyperoxygenated perfluorocarbons as a diluent resulted in significantly improved BCNU concentration ratios, aligning better with desired delivery targets.
- The laboratory findings directly informed the design and implementation of a two-phase clinical protocol for human patients.
Conclusions:
- Theoretical pharmacokinetic modeling for BCNU delivery requires refinement, particularly when using ethanol as a diluent.
- Hyperoxygenated perfluorocarbons represent a superior diluent for enhancing BCNU delivery to brain tumors, improving therapeutic potential.
- This study highlights the successful integration of preclinical laboratory research with clinical application, paving the way for improved brain tumor treatment strategies.